Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens
详细信息 查看全文
- 作者：Takaaki Tokito (1)
Hirotsugu Kenmotsu (1)
Reiko Watanabe (2)
Ichiro Ito (2)
Takehito Shukuya (1)
Akira Ono (1)
Yukiko Nakamura (1)
Asuka Tsuya (1)
Tateaki Naito (1)
Haruyasu Murakami (1)
Toshiaki Takahashi (1)
Yasuhisa Ohde (3)
Haruhiko Kondo (3)
Masahiro Endo (4)
Toru Kameya (2)
Takashi Nakajima (2)
Keita Mori (5)
Nobuyuki Yamamoto (1) - 关键词：LCNEC ; Possible LCNEC ; Small cell carcinoma ; Chemotherapy ; Biopsy
- 刊名：International Journal of Clinical Oncology
- 出版年：2014
- 出版时间：February 2014
- 年：2014
- 卷：19
- 期：1
- 页码：63-67
- 全文大小：233 KB
- 作者单位：Takaaki Tokito (1)
Hirotsugu Kenmotsu (1)
Reiko Watanabe (2)
Ichiro Ito (2)
Takehito Shukuya (1)
Akira Ono (1)
Yukiko Nakamura (1)
Asuka Tsuya (1)
Tateaki Naito (1)
Haruyasu Murakami (1)
Toshiaki Takahashi (1)
Yasuhisa Ohde (3)
Haruhiko Kondo (3)
Masahiro Endo (4)
Toru Kameya (2)
Takashi Nakajima (2)
Keita Mori (5)
Nobuyuki Yamamoto (1)
1. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan
2. Division of Diagnostic Pathology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
3. Division of Thoracic Surgery, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
4. Division of Diagnostic Radiology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
5. Division of Clinical Trial Center, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan - ISSN：1437-7772
文摘
Background It is often difficult to diagnose large cell neuroendocrine carcinomas (LCNEC) of the lung using small biopsy specimens. Some recent studies attempted to diagnose LCNEC using biopsy specimens; in 2011, the International Association for the Study of Lung Cancer pathological panels suggested possible LCNEC as a diagnosis for LCNEC by using biopsy specimens. Here, we compared the chemotherapeutic efficacy in possible LCNEC and LCNEC diagnosed using surgically resected specimens. Methods We retrospectively reviewed patients who received platinum-based chemotherapy as first-line chemotherapy at our institution during September 2002–September 2011. Further, we compared the clinical characteristics, chemotherapeutic responses, and survival outcomes of patients diagnosed as having “LCNEC definite-with those diagnosed as having “possible LCNEC.-/p> Results We selected 34 patients of whom 10 were diagnosed with LCNEC using surgically resected specimens and 24 patients with possible LCNEC were diagnosed using small biopsy specimens. In both groups, almost all patients were men and were smokers. Small-cell carcinoma-based chemotherapy, such as platinum plus irinotecan or platinum plus etoposide, was used for treating 60?% LCNEC patients (6/10) and 67?% possible LCNEC patients. In the LCNEC and possible LCNEC groups, respectively, the response rate was 70 and 54?% (p?=?0.39), median progression-free survival was 2.9 and 4.4?months (p?=?0.20), and median survival time was 12.8 and 9.1?months (p?=?0.50). Conclusion No statistically significant differences were found in chemotherapeutic responses and survival outcomes between the 2 groups, which suggests that chemotherapeutic efficacy is similar in both possible LCNEC and LCNEC.